Table 2.
All patients (n=1020) | Giant cell arteritis (n=158) | ANCA-associated vasculitis (n=294) | Polymyalgia rheumatica (n=323) | Behçet's syndrome (n=97) | Other vasculitis (n=148) | |
---|---|---|---|---|---|---|
Not hospitalised | 512 (50·2%) | 69 (43·7%) | 110 (37·4%) | 187 (57·9%) | 69 (71·1%) | 77 (52·0%) |
Hospitalisation with no supplemental oxygen | 114 (11·2%) | 19 (12·0%) | 30 (10·2%) | 30 (9·3%) | 15 (15·5%) | 20 (13·5%) |
Hospitalisation with ventilation or supplemental oxygen | 239 (23·4%) | 38 (24·1%) | 89 (30·3%) | 71 (22·0%) | 11 (11·3%) | 30 (20·3%) |
Death | 155 (15·2%) | 32 (20·3%) | 65 (22·1%) | 35 (10·8%) | 2 (2·1%) | 21 (14·2%) |
Data are n (%). This analysis excludes 182 patients with missing outcome data. ANCA=antineutrophil cytoplasmic antibody.